Targovax (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway.
| OSLO, Norway, /PRNewswire/ --Targovax (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway. The presentation provided a corporate overview, highlighting the Company’s two platform technologies including clinical data from its lead pipeline asset, ONCOS-102, an oncolytic adenovirus, and the TG cancer vaccine program that targets tumors that express mutated forms of RAS - mutations known to drive cancer. Please see the presentation attached. TRVX DNB presentation The presentation is also available to download at www.targovax.com. CONTACT: For further information, please contact: Media and IR enquires: Simon Conway/Stephanie Cuthbert - FTI Consulting (International) This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Targovax | ||||
Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, Oslo:TRVX, RICS:TRVX.OL |
View original content:
